Stocks and Investing
Stocks and Investing
Fri, November 13, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Martin Auster Maintained (STOK) at Buy with Increased Target to $49 on, Nov 13th, 2020
Martin Auster of Credit Suisse, Maintained "Stoke Therapeutics, Inc." (STOK) at Buy with Increased Target from $42 to $49 on, Nov 13th, 2020.
Martin has made no other calls on STOK in the last 4 months.
There are 2 other peers that have a rating on STOK. Out of the 2 peers that are also analyzing STOK, 0 agree with Martin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Martin
- Charles Duncan of "Cantor Fitzgerald" Initiated at Buy and Held Target at $49 on, Friday, October 23rd, 2020
- Joseph Stringer of "Needham" Initiated at Strong Buy and Held Target at $42 on, Tuesday, September 29th, 2020
Contributing Sources